The origins of BI(G)MED

In 2000, the “Human Genome” project succeeded in sequencing human DNA for the first time. At that time, many researchers intuited that a fundamental portion of the secrets of the immune system were based in genetics.

This project was not an end in and of itself, but the start of the era of genetics in medicine and healthcare.

Among the scientists convinced of the relevance of genetics was Dr. Gilbert GLADY. He took a particular interest in it in the context of his speciality at the time, micro-immunotherapy, with a view to improving the therapeutic potential of this method. Indeed, for more than 15 years, Dr. Glady was the main trainer and promotor of micro-immunotherapy across Europe. His involvement in micro-immunotherapy started in 1983 when he met Dr. Jenaer and learned of his research into immunology and the use of high dilutions for therapeutic purposes. For a decade, he formed part of the micro-immunotherapy research team with Dr. Jenaer and later with his successor, Dr. Marichal.

In 2006, Dr. Glady’s intuition was confirmed: the Nobel prize for medicine was awarded to Craig Mello and Andrew Fire for the discovery of the epigenetic mechanism of “RNA interference”⁽²⁾. In simple terms: the discovery of the mechanism allowing for a gene to be “silenced” within a cell thanks to the influence of microRNAs.

This has nothing to do with genetic manipulation, rather it concerns the modulation/regulation of gene expression.

This revolution in molecular biology has allowed the use of these molecules for therapeutic purposes to be envisaged, by using ultra-low doses that are thus free of side effects.

Since then, the floodgates have opened for regulation of the genome as a therapeutic tool to restore cellular health. Molecular abnormalities can be influenced by regulating the information transmitted by genes without manipulating the human genome.

Thus, in 2010, Bio Immune(G)ene Medicine or BI(G)MED came into being as an extension of micro-immunotherapy. This innovative method relies on the regulation of this molecular information, primarily through microRNAs (miRNA).

In 2012, alongside a group of European physicians, Dr. Glady created the EBMA association, the association responsible for the development and promotion of BI(G)MED in Europe. Thanks to this association, a few hundred therapists have been able to be trained on BI(G)MED throughout l’Europe (France, Belgium, Germany, Austria and Spain).

Today there are almost 150 BI(G)MED formulas. These formulas are manufactured as magistral formulas, which allows for a high degree of flexibility in adjusting their composition according to the very latest scientific research. This is a crucial point, since there are now virtually daily new findings in the domains of immunology and molecular biology (genetics and epigenetics)!

Currently, Dr. Glady spends his time in both clinical practice at his clinic and, alongside a team of training physicians, in the teaching of BI(G)MED in several European countries: Belgium, France, Germany, Austria, Spain and Portugal.

Dr. Glady is the author of several scientific publications on the theme of nanobiotherapy (see the “PUBLICATIONS” page). A number of journals also regularly call upon him to assess the quality of articles submitted for publication as a Reviewer, particularly those addressing the topic of epigenetics.

With his team, he participates in numerous scientific and international medical congresses.